Genmab — September 2018
-
Den kan sagtens blæse nedad igen i morgen.
-
Med andre ord..den er hyper volatil.
-
AbB. Vil nærmere sige Genmab er vidt ved siden af sig selv. Hvis den levede sit eget liv (og Jans) var vi over kurs 2000. Volatiliteten = manipulation af AB. Tror ikke det er tilfældigt der kom et target reducering igår af BoA og det var da også et koordineret udsalg af AB igår da meddelelsen kom. Men vi får se imorgen. Tror den køre vidre opad
-
Bemærker lige, at det nye fase 3 studie - D-VRd non-asct - som blev lagt på CT forleden, kun har lokationer i Canada og Spanien. Det kan ikke være en opfølgning på Griffin, som er for asct-egnede på det amerikanske marked. Gad vist om ikke det skal forstås som en modernisering af Alcyone, altså for den mere velstående del af row-markedet, idet Melphalan trods alt er noget uddateret.
-
God morgen
-
study to use daratumumab, labeled with Zirconium-89 (89Zr ) through deferoxamine (DFO), known as 89Zr-DFO-daratumumab, for PET imaging of multiple myeloma https://clinicaltrials.gov/ct2/show/NCT03665155
-
ASCLEPIOS studies set back to 'recruiting' in clinicaltrials, where Novartis previously said they were fully recruited; who can explain why they would do that? https://clinicaltrials.gov/ct2/history/NCT02792231?A=17&B=18&C=merged
-
They forgot something/someone. It happens to me all the time
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind